Co-Authors
This is a "connection" page, showing publications co-authored by Jean-François Gautier and Jean-Pierre Riveline.
Connection Strength
0.625
-
Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes. EMBO Mol Med. 2020 10 07; 12(10):e13038.
Score: 0.226
-
The COVID-19 lockdown as an opportunity to change lifestyle and body weight in people with overweight/obesity and diabetes: Results from the national French COVIDIAB cohort. Nutr Metab Cardiovasc Dis. 2021 08 26; 31(9):2605-2611.
Score: 0.059
-
Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study. J Infect. 2021 06; 82(6):276-316.
Score: 0.058
-
Stay-at-Home Orders During the COVID-19 Pandemic, an Opportunity to Improve Glucose Control Through Behavioral Changes in Type 1 Diabetes. Diabetes Care. 2021 03; 44(3):839-843.
Score: 0.058
-
Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study. J Infect. 2021 Jan; 82(1):e22-e24.
Score: 0.056
-
Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020 09; 63(9):1953-1957.
Score: 0.056
-
Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jüni P et al [letter]. Diabetologia. 2020 11; 63(11):2491-2494.
Score: 0.056
-
Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020 08; 63(8):1500-1515.
Score: 0.055